loading page

Anti-il-5 in pediatric allergic diseases
  • +1
  • Laura Tenero,
  • Elisa Arturi,
  • Michele Piazza,
  • Giorgio Piacentini
Laura Tenero
University of Verona
Author Profile
Elisa Arturi
Università di Verona
Author Profile
Michele Piazza
Universita' di Verona, Clinica Pediatrica
Author Profile
Giorgio Piacentini
Università di Verona
Author Profile

Abstract

Interleukin (IL)-5 is a potent mediator of the inflammatory cascade in the allergic response.Its predominant role in atopic reactions makes this cytokine an ideal target for blocking the eosinophilic inflammatory hyper-responsiveness to allergens. The management of allergic diseases in childhood – such as severe asthma, atopic dermatitis, and eosinophilic esophagitis - is a challenge. In particular, there are concerns regarding the use of high-dose corticosteroids. Over the last few years, biologics targeting IL-5 or IL-5 receptor - that are mepolizumab, reslizumab, and benralizumab - represent a new, promising, and more personalized therapeutic option.

Peer review status:ACCEPTED

07 Aug 2020Submitted to Pediatric Allergy and Immunology
30 Aug 2020Editorial Decision: Accept